ASCO 2024: A Phase II Trial of Enzalutamide with 5-Alpha Reductase Inhibitors as an ADT–Sparing Approach for Older Men ...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Deepak Kilari discussing results of a phase II trial of enzalutamide with 5-alpha reductase inhibitors as …